Eli Lilly & Co. (LLY)
1,231.94
0.00 (0.00%)
Upcoming Events
Latest Headlines
Eli Lilly selects Veeva Vault CRM for global deployment
August 11, 2026 7:03 AM - StreetInsider
BofA raises obesity market forecast on Lilly stock international strength
August 11, 2026 6:44 AM - StreetInsider
Form 144 ELI LILLY & Co Filed by: Zakrowski Donald A
August 10, 2026 4:32 PM - SEC Filing
Form 4 ELI LILLY & Co For: Aug 07 Filed by: Hakim Anat
August 10, 2026 4:20 PM - SEC Filing
Eli Lilly's weight-loss pill secures first European nod in Britain
August 10, 2026 2:49 PM - StreetInsider
Form 144 ELI LILLY & Co Filed by: Hakim Anat
August 7, 2026 10:30 AM - SEC Filing
Eli Lilly (LLY) PT Raised to $1,419 at Morgan Stanley
August 6, 2026 8:51 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,330 at Wells Fargo
August 6, 2026 6:09 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,400 at BMO Capital
August 6, 2026 5:07 AM - StreetInsider
Form 10-Q ELI LILLY & Co For: Jun 30
August 5, 2026 2:41 PM - SEC Filing
Eli Lilly shares pop as weight-loss drug demand fuels guidance hike
August 5, 2026 7:19 AM - StreetInsider
Form 8-K ELI LILLY & Co For: Aug 05
August 5, 2026 7:05 AM - SEC Filing
Eli Lilly & Co. (LLY) Misses Q2 EPS by 46c ; Offers Guidance
August 5, 2026 6:48 AM - StreetInsider
Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlook
August 5, 2026 6:46 AM - StreetInsider
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
August 5, 2026 6:45 AM - PR NewsWire
Earnings preview: Bernstein sees ‘clear potential for further upside’ in this stock
August 5, 2026 4:04 AM - StreetInsider
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.4 puts into quarter results
August 4, 2026 11:22 AM - StreetInsider
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
August 4, 2026 4:41 AM - StreetInsider
Form 4 ELI LILLY & Co For: Aug 01 Filed by: Seymour Melissa
August 3, 2026 4:43 PM - SEC Filing
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.5 puts with into quarter results
August 3, 2026 11:00 AM - StreetInsider
FDA grants Lilly's olomorasib breakthrough therapy status for pancreatic cancer
August 3, 2026 7:45 AM - StreetInsider
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
August 3, 2026 7:45 AM - PR NewsWire
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
Eli Lilly and Resilience to invest $750 million in US manufacturing
July 30, 2026 8:59 AM - StreetInsider
Lilly to file for next-gen obesity drug approval in early 2027
July 23, 2026 10:54 AM - StreetInsider
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
July 23, 2026 10:12 AM - SEC Filing
Lilly's retatrutide meets goals in two Phase 3 obesity trials
July 23, 2026 6:45 AM - StreetInsider
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026 6:45 AM - PR NewsWire
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
July 22, 2026 10:00 AM - PR NewsWire
Form 4 ELI LILLY & Co For: Jul 20 Filed by: Sulzberger Gabrielle
July 21, 2026 4:41 PM - SEC Filing
Form 4 ELI LILLY & Co For: Jul 20 Filed by: LUCIANO JUAN R
July 21, 2026 4:40 PM - SEC Filing
Form 4 ELI LILLY & Co For: Jul 20 Filed by: Fyrwald J Erik
July 21, 2026 4:39 PM - SEC Filing
Form 4 ELI LILLY & Co For: Jul 20 Filed by: Alvarez Ralph
July 21, 2026 4:38 PM - SEC Filing
Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud
July 21, 2026 7:53 AM - StreetInsider
Novo Nordisk sues Eli Lilly over weight-loss drug ads
July 21, 2026 7:36 AM - StreetInsider
H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral
July 20, 2026 7:17 AM - StreetInsider
UBS Reiterates Buy Rating on Eli Lilly (LLY) on Deal to Acquire ATAI
July 17, 2026 9:13 AM - StreetInsider
Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'
July 16, 2026 10:00 AM - StreetInsider
Eli Lilly to acquire AtaiBeckley for up to $3.8B
July 16, 2026 6:45 AM - StreetInsider
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 16, 2026 6:45 AM - PR NewsWire
Lilly Said To Near Deal For Psychedelic Drugmaker Ataibeckley - Bloomberg
July 15, 2026 7:09 PM - StreetInsider
Three Biotechs Deliver Catalysts to Watch
July 15, 2026 10:43 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,600 at Citi
July 15, 2026 5:02 AM - StreetInsider
Lilly’s Retevmo approved by FDA for RET Tumors
July 14, 2026 2:27 PM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,385 at Bernstein SocGen Group
July 14, 2026 6:20 AM - StreetInsider
Teva lawsuit against Eli Lilly over Forteo revived by appeals court
July 13, 2026 3:27 PM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,273 at Guggenheim
July 13, 2026 6:51 AM - StreetInsider
/C O R R E C T I O N -- Eli Lilly and Company/
July 9, 2026 1:17 PM - PR NewsWire
Lilly to present 16 Alzheimer's abstracts at AAIC 2026 in London
July 9, 2026 7:31 AM - StreetInsider
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
July 9, 2026 7:30 AM - PR NewsWire
Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
July 8, 2026 4:36 PM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,370 at Truist Securities
July 8, 2026 8:52 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,347 at Morgan Stanley
July 8, 2026 8:08 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,500 at RBC Capital
July 8, 2026 7:41 AM - StreetInsider
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
July 7, 2026 3:02 PM - SEC Filing
Eli Lilly (LLY) PT Raised to $1,400 at JPMorgan
July 7, 2026 8:16 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,350 at Cantor Fitzgerald as Strong Q2 Results Likely
July 6, 2026 6:45 AM - StreetInsider
Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
July 6, 2026 6:43 AM - StreetInsider
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
July 1, 2026 9:05 AM - StreetInsider
RBC Capital Reiterates Outperform Rating on Eli Lilly (LLY)
July 1, 2026 7:59 AM - StreetInsider
Innovent and Lilly strike China deal for breast cancer drug
June 30, 2026 3:26 AM - StreetInsider
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
June 30, 2026 12:00 AM - PR NewsWire
FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
June 29, 2026 4:28 PM - StreetInsider
FDA selects 7 companies for domestic drug manufacturing pilot
June 29, 2026 4:20 PM - StreetInsider
Sandoz submits generic obesity drug applications to FDA
June 29, 2026 6:14 AM - StreetInsider
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
June 26, 2026 1:40 PM - SEC Filing
Lilly's Jaypirca gets EU approval recommendation for CLL
June 26, 2026 7:17 AM - StreetInsider
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
June 26, 2026 7:16 AM - PR NewsWire
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026 6:45 AM - PR NewsWire
Lilly completes acquisition of Centessa Pharmaceuticals
June 24, 2026 8:45 AM - StreetInsider
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
June 24, 2026 8:45 AM - PR NewsWire
Form 11-K ELI LILLY & Co For: Dec 31
June 23, 2026 3:27 PM - SEC Filing
Eli Lilly plans European weight-loss pill launch by early 2027
June 23, 2026 12:20 PM - StreetInsider
Sangamo files Chapter 11, agrees to sell assets to Lilly, Astellas
June 23, 2026 8:05 AM - StreetInsider
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.6% Yield
June 22, 2026 11:00 AM - StreetInsider
Lilly declares third-quarter 2026 dividend
June 22, 2026 11:00 AM - PR NewsWire
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
June 22, 2026 9:05 AM - StreetInsider
This digital health stock is ready to re-rate higher: Goldman
June 22, 2026 9:00 AM - StreetInsider
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald as Injectable Obesity TRx Down
June 22, 2026 7:37 AM - StreetInsider
Oral Wegovy reaches 33% of total prescriptions by May
June 18, 2026 5:47 AM - StreetInsider
Form 4 ELI LILLY & Co For: Jun 15 Filed by: Sulzberger Gabrielle
June 16, 2026 4:26 PM - SEC Filing
Form 4 ELI LILLY & Co For: Jun 15 Filed by: LUCIANO JUAN R
June 16, 2026 4:25 PM - SEC Filing
Form 4 ELI LILLY & Co For: Jun 15 Filed by: Fyrwald J Erik
June 16, 2026 4:14 PM - SEC Filing
Form 4 ELI LILLY & Co For: Jun 15 Filed by: Alvarez Ralph
June 16, 2026 4:13 PM - SEC Filing
Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)
June 15, 2026 4:08 PM - StreetInsider
BMO Capital on Eli Lilly (LLY): 'Early Data for AJ1-11095 Impress at EHA'
June 15, 2026 10:11 AM - StreetInsider
Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
June 14, 2026 8:05 AM - StreetInsider
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026 3:15 AM - PR NewsWire
Leerink highlights drug demand rebound after Memorial Day
June 12, 2026 2:42 PM - StreetInsider
Form 4 ELI LILLY & Co For: Jun 10 Filed by: Yuffa Ilya
June 11, 2026 4:23 PM - SEC Filing
Form 144 ELI LILLY & Co Filed by: Yuffa Ilya
June 10, 2026 11:04 AM - SEC Filing
Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026 9:30 AM - PR NewsWire
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
June 10, 2026 6:05 AM - StreetInsider
FDA approves Lilly's EBGLYSS for eight-week dosing in atopic dermatitis
June 9, 2026 6:19 PM - StreetInsider
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026 6:19 PM - PR NewsWire
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
June 9, 2026 2:31 PM - StreetInsider
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
June 9, 2026 4:00 AM - BizWire
Lilly's oral diabetes drug outperforms rival in late-stage trials
June 8, 2026 2:31 PM - StreetInsider
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 8, 2026 2:30 PM - PR NewsWire
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
June 8, 2026 9:40 AM - StreetInsider
Truist on Eli Lilly (LLY): 'We see near-term and longer-term areas for growth'
June 8, 2026 9:21 AM - StreetInsider
Lilly reports weight loss data for Foundayo across menopause stages
June 8, 2026 2:56 AM - StreetInsider
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 7, 2026 11:00 AM - PR NewsWire
Pfizer targets obesity market with monthly weight-loss injection data
June 6, 2026 6:03 PM - StreetInsider
Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide
June 6, 2026 6:03 PM - StreetInsider
Eli Lilly reports positive results for obesity drug retatrutide trials
June 6, 2026 2:53 PM - StreetInsider
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
June 6, 2026 2:30 PM - PR NewsWire
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
June 5, 2026 7:38 AM - StreetInsider
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
June 5, 2026 7:05 AM - StreetInsider
ADA 2026 preview: All eyes on these 2 stocks
June 4, 2026 7:00 PM - StreetInsider
Weight Watchers integrates with Eli Lilly's LillyDirect platform
June 4, 2026 8:03 AM - StreetInsider
Lilly cuts Germany investment plan in half over healthcare reforms
June 3, 2026 1:17 PM - StreetInsider
Lilly to present hematology data at European meeting in Stockholm
June 2, 2026 9:30 AM - StreetInsider
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
June 2, 2026 9:30 AM - PR NewsWire
Form 25-NSE ELI LILLY & Co Filed by: NEW YORK STOCK EXCHANGE LLC
June 2, 2026 9:17 AM - SEC Filing
Camurus (CAMX) announces expansion of Lilly collaboration, decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology
June 1, 2026 11:35 AM - StreetInsider
Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
June 1, 2026 9:05 AM - StreetInsider
Lilly's Retevmo reduces cancer recurrence risk by 83% in trial
June 1, 2026 2:53 AM - StreetInsider
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide
May 31, 2026 11:21 PM - StreetInsider
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026 8:01 AM - PR NewsWire
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 28, 2026 3:02 PM - SEC Filing
Lilly to present diabetes, obesity drug data at ADA conference
May 28, 2026 1:00 PM - StreetInsider
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026 1:00 PM - PR NewsWire
CVS Adds Lilly's Zepbound To Preferred Drug List In Reversal
May 28, 2026 6:47 AM - StreetInsider
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026 6:45 AM - PR NewsWire
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026 11:15 AM - PR NewsWire
Lilly acquires three infectious disease companies for up to $3.83 billion
May 26, 2026 6:45 AM - StreetInsider
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026 6:45 AM - PR NewsWire
Eli Lilly & Co. (LLY) to buy three vaccine firms for up to $4B - WSJ
May 26, 2026 6:39 AM - StreetInsider
Lilly's VERVE-102 reduces cholesterol by up to 62% in phase 1b trial
May 26, 2026 5:50 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,251 at BofA Securities
May 26, 2026 5:26 AM - StreetInsider
Leerink Reiterates Outperform Rating on Eli Lilly (LLY)
May 26, 2026 3:05 AM - StreetInsider
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026 8:45 AM - PR NewsWire
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 22, 2026 2:05 PM - SEC Filing
China holds roundtable with over 50 foreign pharmaceutical firms
May 22, 2026 9:54 AM - StreetInsider
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
May 22, 2026 9:24 AM - StreetInsider
Eli Lilly reports weight loss data for obesity drug in older adults
May 22, 2026 8:50 AM - StreetInsider
Lilly to present oncology data at ASCO 2026 meeting
May 21, 2026 5:02 PM - StreetInsider
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026 5:00 PM - PR NewsWire
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
May 21, 2026 9:00 AM - StreetInsider
Lilly's retatrutide shows significant weight loss in phase 3 trial
May 21, 2026 6:45 AM - StreetInsider
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026 6:45 AM - PR NewsWire
Form 8-K ELI LILLY & Co For: May 20
May 20, 2026 4:31 PM - SEC Filing
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 20, 2026 4:22 PM - SEC Filing
Eli Lilly & Co. (LLY) Acquires Engage Biologics for Up to $202M in Cash
May 20, 2026 9:37 AM - StreetInsider
Form 4 ELI LILLY & Co For: May 18 Filed by: Sulzberger Gabrielle
May 19, 2026 4:20 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 18 Filed by: LUCIANO JUAN R
May 19, 2026 4:19 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 18 Filed by: Fyrwald J Erik
May 19, 2026 4:18 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 18 Filed by: Alvarez Ralph
May 19, 2026 4:16 PM - SEC Filing
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
May 18, 2026 10:00 AM - PR NewsWire
Eli Lilly loses Supreme Court appeal of $194 million fraud award
May 18, 2026 9:57 AM - StreetInsider
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
May 16, 2026 11:00 AM - PR NewsWire
Lilly and UNICEF collaborate to give millions of children a healthier start
May 14, 2026 7:00 AM - PR NewsWire
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
May 13, 2026 9:24 AM - StreetInsider
Eli Lilly launches Alzheimer's drug in India at $957 per vial
May 13, 2026 5:57 AM - StreetInsider
Full Article List
